TASSINARI, ELISA
TASSINARI, ELISA
Borsisti
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
2022 Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
2023 Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo, Alessandro; Massari, Francesco; Mollica, Veronica
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report
2024 Casadio, Chiara; Tassinari, Elisa; Carloni, Riccardo; Rossi, Romina; Tenti, Maria Valentina; Fabbri, Laura; Maltoni, Marco
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
2024 Rosellini, Matteo; Mollica, Veronica; Marchetti, Andrea; Coluccelli, Sara; Giunchi, Francesca; Tassinari, Elisa; Ricci, Costantino; Fiorentino, Michelangelo; Tallini, Giovanni; De Biase, Dario; Massari, Francesco
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
2023 Santoni, Matteo; Rizzo, Alessandro; Kucharz, Jakub; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Tassinari, Elisa; Monteiro, Fernando Sabino Marques; Soares, Andrey; Molina-Cerrillo, Javier; Grande, Enrique; Battelli, Nicola; Massari, Francesco
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
2022 Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F.
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
2023 Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, Costantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
2023 Rizzo, Alessandro; Mollica, Veronica; Tateo, Valentina; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; De Luca, Raffaele; Santoni, Matteo; Massari, Francesco
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis
2023 Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers
2022 Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fiorentino M.; Massari F.
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report
2023 Elisa Tassinari, Nicole Conci, Giacomo Battisti, Francesco Porta, Valerio Di Scioscio, Maria Giulia Pirini, Dario de Biase, Maria Concetta Nigro, Miriam Iezza, Fausto Castagnetti, Luigi Lovato, Stefano Fanti, Maria Abbondanza Pantaleo, Margherita Nannini
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022 Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D.
Prostate cancer and novel pharmacological treatment options - what's new for 2022?
2023 Marchetti, Andrea; Tassinari, Elisa; Rosellini, Matteo; Rizzo, Alessandro; Massari, Francesco; Mollica, Veronica
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial
2023 Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab
2023 Mollica, Veronica; Tassinari, Elisa; Santoni, Matteo; Marchese, Paola Valeria; Giunchi, Francesca; Maloberti, Thais; Tateo, Valentina; Ricci, Costantino; Rosellini, Matteo; Marchetti, Andrea; Fiorentino, Michelangelo; Biase, Dario De; Massari, Francesco
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
2023 Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Tateo, Valentina; Tassinari, Elisa; Rosellini, Matteo; Massafra, Raffaella; Santoni, Matteo; Massari, Francesco
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
2022 De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
2022 Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy | Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa...; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco | 2022-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; My...int Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2022 [MOUSEION04].pdf; cancers-14-04142-s001.zip |
| An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma | Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo,... Alessandro; Massari, Francesco; Mollica, Veronica | 2023-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report | Casadio, Chiara; Tassinari, Elisa; Carloni, Riccardo; Rossi, Romina; Tenti, Maria Valentina; Fabb...ri, Laura; Maltoni, Marco | 2024-01-01 | CASE REPORTS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw | Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.;... Massari F. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Bone agents PCa].pdf |
| Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis | Rosellini, Matteo; Mollica, Veronica; Marchetti, Andrea; Coluccelli, Sara; Giunchi, Francesca; Ta...ssinari, Elisa; Ricci, Costantino; Fiorentino, Michelangelo; Tallini, Giovanni; De Biase, Dario; Massari, Francesco | 2024-01-01 | PATHOLOGY, RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis | Santoni, Matteo; Rizzo, Alessandro; Kucharz, Jakub; Mollica, Veronica; Rosellini, Matteo; Marchet...ti, Andrea; Tassinari, Elisa; Monteiro, Fernando Sabino Marques; Soares, Andrey; Molina-Cerrillo, Javier; Grande, Enrique; Battelli, Nicola; Massari, Francesco | 2023-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer | Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F. | 2022-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |
| How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? | Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, C...ostantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco | 2023-01-01 | MOLECULAR DIAGNOSIS & THERAPY | - | 1.01 Articolo in rivista | Molecular Diagn Ther 2023 [Neoadj UC].pdf |
| Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study | Rizzo, Alessandro; Mollica, Veronica; Tateo, Valentina; Tassinari, Elisa; Marchetti, Andrea; Rose...llini, Matteo; De Luca, Raffaele; Santoni, Matteo; Massari, Francesco | 2023-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis | Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronic...a; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco | 2023-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers | Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fio...rentino M.; Massari F. | 2022-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
| Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report | Elisa Tassinari, Nicole Conci, Giacomo Battisti, Francesco Porta, Valerio Di Scioscio, Maria Giul...ia Pirini, Dario de Biase, Maria Concetta Nigro, Miriam Iezza, Fausto Castagnetti, Luigi Lovato, Stefano Fanti, Maria Abbondanza Pantaleo, Margherita Nannini | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | Tassinari, Conci Front Oncol 2023.pdf |
| Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis | Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti... G.; Campana D. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Vescica_SEER.pdf; curroncol-29-00461-s001.zip |
| Prostate cancer and novel pharmacological treatment options - what's new for 2022? | Marchetti, Andrea; Tassinari, Elisa; Rosellini, Matteo; Rizzo, Alessandro; Massari, Francesco; Mo...llica, Veronica | 2023-01-01 | EXPERT REVIEW OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial | Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco | 2023-01-01 | EUROPEAN UROLOGY | - | 1.01 Articolo in rivista | - |
| TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab | Mollica, Veronica; Tassinari, Elisa; Santoni, Matteo; Marchese, Paola Valeria; Giunchi, Francesca...; Maloberti, Thais; Tateo, Valentina; Ricci, Costantino; Rosellini, Matteo; Marchetti, Andrea; Fiorentino, Michelangelo; Biase, Dario De; Massari, Francesco | 2023-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study | Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Tateo, Valentina; Tassinari, Elisa; Rose...llini, Matteo; Massafra, Raffaella; Santoni, Matteo; Massari, Francesco | 2023-01-01 | CLINICAL AND EXPERIMENTAL MEDICINE | - | 1.01 Articolo in rivista | Clin Exp Med. 2023 [MOUSEION 06].pdf |
| The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy | De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Spe...randi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-05845-v2.pdf |
| Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy | Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M. | 2022-01-01 | CANCER MANAGEMENT AND RESEARCH | - | 1.01 Articolo in rivista | CMAR 2022 [Eli UC after first line].pdf |